Publication
Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors.
Journal Paper/Review - Feb 20, 2015
Joerger M, Hess D, Delmonte Angelo, Gallerani E, Barbieri P, Pace S, Sessa C
Units
PubMed
Doi
Contact
Citation
Joerger M, Hess D, Delmonte A, Gallerani E, Barbieri P, Pace S, Sessa C. Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors. Invest New Drugs 2015; 33:472-9.
Type
Journal Paper/Review (English)
Journal
Invest New Drugs 2015; 33
Publication Date
Feb 20, 2015
Issn Electronic
1573-0646
Pages
472-9
Brief description/objective
This is a first-in-human, phase I, dose-escalation study to determine the maximum tolerated dose (MTD) of intravenous, flat-dosed ST-1968 (namitecan), a new hydrophilic camptothecan derivative.